Oruka Therapeutics is the lead sponsor of 6 current clinical trials in our USA and EU (CTIS) registers. 3 are recruiting patients now. All registered phases are Phase 2. The drugs named most often in its trials are ORKA-001 and ORKA-002. The most-studied condition is Plaque Psoriasis.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
NCT07783542 · Hidradenitis Suppurativa (HS)
Drug: ORKA-002 |
Phase 2 | Recruiting | 2026-08 | USA |
|
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: ORKA-001 |
Phase 2 | Recruiting | 2026-02 | USA |
|
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: ORKA-002 |
Phase 2 | Recruiting | 2026-03 | USA |
|
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: ORKA-001 |
Phase 2 | Active, closed | 2025-12 | USA |
|
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: ORKA-001 |
Phase 2 | Active, closed | 2025-07 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Oruka Therapeutics as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
2026-526898-42-00 · Skin and Connective Tissue Diseases
Drug: ORKA-001 |
Phase 2 | Authorised | Spain, Germany |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 3 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Alumis | 2 |
| InventisBio | 2 |
Sponsors with the most current trials registered for this condition.
Oruka Therapeutics is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are ORKA-001 (4) and ORKA-002 (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.